Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 1:53 PM
Ignite Modification Date: 2025-12-24 @ 1:53 PM
NCT ID: NCT05928195
Eligibility Criteria: Inclusion Criteria: * 18-45 years, inclusive * Physically active (\>=150 min/wk or \>=75 min/wk Moderate or Vigorous PA) for \>=3 months * BMI \<= 30 kg/m2 * Otherwise healthy * Habitual caffeine consumption \>=200 mg/day OR 1-week washout of current caffeine usage prior to participation Exclusion Criteria: * Current injury or illness that precludes exercise participation * Current nicotine or cannabis use * Use of prescription ADD/ADHD, anti-depressant, or other central acting medication, or previously diagnosed ADD/ADHD, clinically depressed, or generalized anxiety disorder * Current taking prescription stimulants (i.e., Adderall, Ritalin, Vyvanse, etc.) * Participants with a history of metabolic, hepatorenal, musculoskeletal, autoimmune, or neurologic disease; or currently taking thyroid, hormonal, hyperlipidemic, hypoglycemic, anti-hypertensive, anti-inflammatory, or anti-coagulant medications. * Treated for Metabolic Syndrome or having been clinically diagnosed with, or taking medication for a cardiometabolic-disorder (e.g., Pre-diabetes, Type II diabetes, high blood pressure, obesity, hypercholesterolemia, etc.) * Currently pregnant or lactating * Diagnosed allergy to any ingredient present within the study treatments * Current competitive NCAA athlete * Inability or unwillingness to comply with the controls and conditions of the study
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 45 Years
Study: NCT05928195
Study Brief:
Protocol Section: NCT05928195